0001193125-19-281545.txt : 20191101 0001193125-19-281545.hdr.sgml : 20191101 20191101114456 ACCESSION NUMBER: 0001193125-19-281545 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20191101 DATE AS OF CHANGE: 20191101 EFFECTIVENESS DATE: 20191101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALDER BIOPHARMACEUTICALS INC CENTRAL INDEX KEY: 0001423824 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900134860 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-36431 FILM NUMBER: 191185870 BUSINESS ADDRESS: STREET 1: 11804 NORTH CREEK PARKWAY SOUTH CITY: BOTHELL STATE: WA ZIP: 98011 BUSINESS PHONE: 425-205-2900 MAIL ADDRESS: STREET 1: 11804 NORTH CREEK PARKWAY SOUTH CITY: BOTHELL STATE: WA ZIP: 98011 15-12B 1 d827666d1512b.htm 15-12B 15-12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-36431

 

 

 

Alder BioPharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

11804 North Creek Parkway South

Bothell, Washington 98011

(425) 205-2900

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.0001 per share

2.50% Convertible Senior Notes due 2025

Preferred Stock, par value $0.0001 per share*

Warrants*

Debt Securities*

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)   ☒**
Rule 12g-4(a)(2)   ☐
Rule 12h-3(b)(1)(i)   ☒
Rule 12h-3(b)(1)(ii)   ☐
Rule 15d-6   ☐
Rule 15d-22(b)   ☐

Approximate number of holders of record as of the certification or notice date:

 

Common Stock, par value $0.0001 per share:    one (1)
2.50% Convertible Senior Notes due 2025:    thirty-eight (38)
Preferred Stock, par value $0.0001 per share:*    zero (0)
Debt Securities:*    zero (0)
Warrants:*    zero (0)

 

*

None issued under a registration statement other than the 2.50% Convertible Senior Notes due 2025; originally registered on Form S-3 (File No. 333-216199) and subsequently removed and withdrawn from registration pursuant to a post-effective amendment to the foregoing Form S-3, which amendment was effective as of October 22, 2019.

**

Only with respect to Common Stock, par value $0.0001 per share.

Pursuant to the requirements of the Securities Exchange Act of 1934, Alder BioPharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: November 1, 2019     By:  

/s/ Peter Anastasiou

        Name: Peter Anastasiou
        Title: President